← Back to Search

Dietary Supplement

Synaquell for Brain Function in Athletes

N/A
Waitlist Available
Led By Michael Stuart, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, postseason (approximately 6 months)

Summary

This trial is testing if the brain health supplement Synaquell can improve brain function in youth ice hockey players. The study will compare results from those taking Synaquell and others over several months using different brain health tests.

Who is the study for?
This trial is for medically cleared youth ice hockey players who speak English fluently. It's not suitable for those with pacemakers, defibrillators, in-ear hearing devices, skull implants, seizure history or allergies to SynaquellTM ingredients, rubbing alcohol or EEG gel.
What is being tested?
The study tests the effects of a dietary supplement called Synaquell(TM) on brain function in these athletes. Participants will either receive Synaquell(TM) or a placebo without knowing which one they are taking.
What are the potential side effects?
Potential side effects aren't specified but may relate to individual sensitivity to the ingredients of Synaquell(TM) or the placebo used in this research.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, postseason (approximately 6 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, postseason (approximately 6 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in N100 Amplitude
Change in N100 Latency
Change in N400 Amplitude
+4 more
Secondary study objectives
Change in King-Devick Test (KDT) scores

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Synaquell Male GroupExperimental Treatment1 Intervention
Male youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
Group II: Synaquell Female GroupExperimental Treatment1 Intervention
Female youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
Group III: Placebo Male GroupPlacebo Group1 Intervention
Male youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
Group IV: Placebo Female GroupPlacebo Group1 Intervention
Female youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Synaquell
2021
N/A
~140

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Nutritional supplements like Synaquell (TM) typically contain vitamins, minerals, and bioactive compounds that support brain health by enhancing cognitive function, protecting against oxidative stress, and improving brain metabolism. These mechanisms are important for healthy subjects as they help maintain optimal brain function, prevent cognitive decline, and enhance mental performance.
Potential role of phytochemicals in metabolic syndrome prevention and therapy.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,326 Previous Clinical Trials
3,059,401 Total Patients Enrolled
Michael Stuart, MDPrincipal InvestigatorMayo Clinic
3 Previous Clinical Trials
4,100 Total Patients Enrolled

Media Library

Placebo (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT05498818 — N/A
Healthy Subjects Research Study Groups: Placebo Male Group, Synaquell Male Group, Synaquell Female Group, Placebo Female Group
Healthy Subjects Clinical Trial 2023: Placebo Highlights & Side Effects. Trial Name: NCT05498818 — N/A
Placebo (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05498818 — N/A
~27 spots leftby Nov 2025